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Introduction: Granulomatosis with polyangiitis poses a significant diagnostic dilemma due its diverse
presentations. Seemly isolated sites of disease, such as oral ulcers, may present to physicians working in primary
care settings, the emergency room, and subspecialty fields as well as to dentists. Oral presentations are particularly
challenging to identify and require a high index of suspicion and a detailed knowledge of the condition in order to
diagnose and treat. We detail a case of granulomatosis with polyangiitis presenting as necrotizing gingivitis, one of
the first of its kind to be reported.
Case presentation: An otherwise healthy 32-year-old, Caucasian woman presented to various physicians with
progressive, painful oral ulcers. Following consultations with multiple primary care physicians and subspecialties,
an initial diagnosis of severe infectious necrotizing gingivitis was made resulting in combination antibiotic treatment
as well as surgical debridement involving extraction of all maxillary and three mandibular teeth. With the discovery
of a positive cytoplasmic anti-neutrophil cytoplasmic antibody and a constellation of associated systemic symptoms,
our patient was subsequently diagnosed with granulomatosis with polyangiitis. The treatment regimen of rituximab
and methylprednisone was chosen in consideration of our patient’s desire for future fertility and has been successful
in inducing and maintaining remission.
Conclusions: Following the case presentation, we review the current literature regarding granulomatosis with
polyangiitis presentation, diagnosis and treatment. In discussing features of granulomatosis with polyangiitis
presentation, diagnostic tests, and important new treatment options, we seek to enable physicians of all specialties
to better recognize and begin appropriate treatment for this complex condition.
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The identification of systemic vasculitides is one of most
challenging diagnostic puzzles in clinical medicine. The
diagnosis of the vasculitis granulomatosis with polyangii-
tis (GPA), previously Wegener’s, is particularly difficult
due to its manifold presentations; from isolated derma-
tologic, to respiratory, to ophthalmologic manifestations,
this dangerous systemic illness may be mistaken for an
isolated complaint. We present the case of a 32-year-old
woman who presented to several primary care physicians
with the complaint of painful, progressing oral ulcers.
The steps in reaching the surprising diagnosis of GPA are
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article, unless otherwise stated.regimen that facilitated our patient’s desire for retaining
fertility. We provide context for the case by reviewing the
current literature with regard to various GPA presenta-
tions, criteria for diagnosis, and new treatment options.
Case presentation
A 32-year-old, otherwise healthy Caucasian woman pre-
sented to her dentist with small, painful ulcers on her
maxillary gingiva (Figure 1). An amoxicillin regimen for
the presumed tooth infection was ineffective. Over the
next month, the ulcer spread to involve the mandibular
gingival, posterior alveolus, and retromolar trigone; con-
currently; she became constitutionally unwell prompting a
second course of antibiotics. After several days of worsen-
ing symptoms, our patient presented to the emergency
department with unbearable trismus, necrotizing ulcers,
and otalgia, requiring hospital admission. On admission,ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Initial appearance of ulcers on maxillary gingiva.
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(WBC) count (16.9×109/L), normal renal function (urea
7.2mmol/L, estimated glomerular filtration rate (eGFR)
116ml/min/1.73m2, creatinine 53umol/L), and a very high
C-reactive protein (CRP) (193.3mg/L). Necrotizing gingi-
vitis with osteomyelitis was diagnosed and metronidazole
and ceftriaxone were prescribed under specialty care.
Within the first three days in hospital the necrotizing
region expanded into the maxillary and mandibular bone
and eroded through the maxillary antrum, resulting in
aoroantral fistula. Extraction of all maxillary teeth and
three mandibular teeth, as well as extensive surgical de-
bridement and curettage of the maxillary bone were per-
formed. Further progression prompted a second round
of debridement and curettage five days later.
Our patient failed to recover with antibiotic treatment
and surgery throughout these first nine days in hospital.
Her severely declining clinical status was apparent; she
experienced disabling fatigue, fevers, and drenching
night sweats. Morning joint stiffness throughout the ex-
tremities as well as a numb patch on the right thumb
was noted. In addition, our patient’s otalgia had wors-
ened as she developed hearing loss associated with bilat-
eral tympanic membrane perforation. Laboratory testing
demonstrated leukocytosis, anemia (83g/L from 128g/L
on admission), an increasing CRP (299.2mg/L from
193.3mg/L), and hematuria with red blood cell casts.
At this point, a positive cytoplasmic anti-neutrophil
cytoplasmic antibody (c-ANCA) test and associated pro-
teinase 3 ANCA (PR3-ANCA) levels (744.5U/ml) were
received, suggesting a diagnosis of acute GPA. Our pa-
tient was reexamined in detail with specific attention to
her history and physical examination features relevant to
a GPA diagnosis. A thorough history revealed an active,
healthy lifestyle without any significant stressors or past
illnesses. Of possible consequence, we noted that she had
occupational and personal exposure to various herbicides,black mold, and industrial solvents including acetone,
without the use of personal protective equipment over the
past 10 years. A physical examination revealed a gravely ill
patient with trismus, hemorrhagic gingiva, inflamed otic
canals obscured by serosanguinous discharge, bilaterally
reduced air entry, inspiratory crackles as well as a patch of
anesthesia on the palmar surface of the right thumb. Sev-
eral 3 to 4mm erythematous nodular lesions on the dor-
sum of her left hand were observed.
Following the diagnosis of GPA, our patient was imme-
diately treated with methylprednisone pulse therapy, and
after several days intravenous (IV) cyclophosphamide was
added. Relevant imaging tests and biopsies were carried
out. Chest computed tomography (CT) imaging demon-
strated multiple nodules, including a 2.8×3.0×1.9cm cen-
trally cavitating pleural-based mass in the left apex, as well
as bilateral pleural effusions. Histopathological examin-
ation of endobronchial biopsies from the right bronchus
intermedius demonstrated necrotizing mucosal erosion
and active inflammation.
Within days of treatment, dramatic improvement was
seen. Our patient’s conductive hearing loss and otalgia
began improving and laboratory test abnormalities in-
cluding the previously elevated WBC count and CRP
reversed. Due to our patient’s fertility concerns, ritux-
imab - IV, 375mg/m2 - was substituted for cyclophos-
phamide. A four-week infusion cycle of rituximab along
with prednisone, 60mg daily, was the core remission-
inducing treatment regimen. A debriding procedure two
weeks into treatment found that necrotic spread in her
jaw had been halted. Chest CT imaging at one month
demonstrated resolving lesions and no adverse changes.
Our patient was subsequently placed on a disease-
modifying therapy regimen, including azathioprine and
prednisone, and was followed by rheumatology, respirol-
ogy and dental surgery specialists. Three months following
her acute presentation, she underwent a partial surgical
repair of the eroded maxillary antrum via iliac crest bone
grafting. She continues to receive careful follow-up re-
garding her oral health post teeth extraction, repair of her
maxillary antrum, as well as the severe damage done by
the necrotizing vasculitic process to her left Eustachian
tube and tympanic membrane. Our patient is regularly
monitored through complete blood count (CBC), electro-
lyte, renal function, and CRP testing. Despite dealing with
sequelae of the acute GPA, she has remained in remission
from GPA for more than 15 months.
Discussion
Until the latter 20th century GPA was universally fatal,
usually within weeks to months. Current diagnostic and
treatment methods have reduced this mortality rate to
less than 5 percent. Nevertheless, half of those diagnosed
suffer from some form of long-term consequence due to
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is critical that physicians recognize the condition early
to minimize harm and reduce mortality risk in this po-
tentially rapidly progressive disease.
Presentations of GPA: critical recognition of clinical signs
and symptoms
GPA can have dramatically varied presentations, ranging
from an isolated ulcer or rash to fulminant multisystem
crisis (Table 1). The underlying pathophysiological mech-
anism of tissue involves intravascular and extravascular
granuloma formation associated with necrotizing vasculitis
of small- and medium-sized arteries and veins. The fre-
quency of this disease is equal between men and woman,
and is more common in Caucasians. Although the average
age of onset is 50, it can present at any age [1].
Most patients experience prodromal constitutional
symptoms, including fever, weight loss, night sweats, and
joint stiffness. Gradual hearing loss and chronic nasal
stuffiness or epistaxis are also common. The prodrome
can last for months before progression occurs. Over 90
percent of patients first seek medical help for upper or
lower airway symptoms, such as long-standing upper re-
spiratory tract infections or shortness of breath [4].
The acute vasculitic phase can be global in scope, involv-
ing any system. Presentations of pulmonary hemorrhage or
rapidly progressive glomerulonephritis are the most con-
cerning; these can be fatal in hours or days [3]. Previously
described oral manifestations of GPA include strawberry
gingivitis, oral petechia and soft palate ulcers [5,6]. As de-
scribed in the current case, patients transitioning from a
prodromal phase to active vasculitis may present with
features similar to a localized oral or cutaneous infec-
tion unresponsive to antibiotics. By maintaining a high
index of suspicion and an awareness of the possible
presentations, a physician is likely to perceive the clinicalTable 1 Locations and forms of GPA presentation
Site Presentations
Upper airway [1,2] Oral or nasal ulcers, strawberry gums, strawberry
respiratory tract or ear ‘infections’ , otitis, vestibul
or sensorineural deafness
Lower airways [1,2] Subglottic stenosis, pulmonary nodular infiltrates
‘ground-glass’ infiltrations, pleurisy
Kidneys [1,3] Rapidly progressing glomerulonephritis - necroti
Musculoskeletal [1,2] Myalgias, migratory pauciarticular or polyarticula
Eye [1,2,4] Scleritis, episcleritis, orbital pseudotumor, propto
Skin [1,2] Palpable purpura, ulcers, leucocytoclastic vasculit
gangrene
Nervous system [1,2] Peripheral neuropathy, mononeuritis multiplex, c
Additional rare
presentations [2,3]
Myocarditis, pericarditis, cerebral vasculitis, mass
orbit, breast, prostate, ovary, parotid)signs and symptoms of GPA and can move on to appro-
priate diagnostic testing: ANCA testing and histological
examination.
Diagnostic clues: distinguishing laboratory and
histopathological tests for GPA
ANCA testing and/or histological examination of af-
fected tissues represent the final steps necessary for a
complete GPA diagnosis. As different vasculitides have
differing ANCA test results, it is useful to carry out an
ANCA test panel including two primary types of testing.
Immunofluorescence testing determines c-ANCA or peri-
nuclear anti-neutrophil cytoplasmic antibody (p-ANCA)
presence. Enzyme immunoassays demonstrate the pres-
ence of PR3-ANCA and myeloperoxidase (MPO)-ANCA.
c-ANCA, generally corresponding to PR3-ANCA positiv-
ity, has the greatest sensitivity (64 percent) and specificity
(95 percent) for GPA, while p-ANCA and MPO-ANCA
positivity generally corresponds to other vasculitides, such
as microscopic polyangiitis and eosinophilic granulomato-
sis with polyangiitis (Churg-Strauss syndrome) [7]. In con-
sidering the use of ANCA testing it is important to note
that the test sensitivity varies depending on disease pro-
gression. PR3-ANCA is most sensitive for GPA - sensitivity
greater than 90 percent - in a setting with clear clinical
signs and symptoms of GPA [8]. Additional laboratory
tests that supported a GPA diagnosis include a high
erythrocyte sedimentation rate (ESR), anemia, thrombocy-
tosis and leukocytosis [3].
On histopathological examination, there are three
classic features that can provide confirmation of a GPA
diagnosis - granulomatous inflammation, aseptic vasculitis
and necrosis [1,3,4]. These findings, however, are not ne-
cessary prior to proceeding with appropriate treatment,
particularly when respiratory or renal damage is imminent.
Moreover, obtaining a successful biopsy of affected tissueFrequency of disease occurrence at
site throughout disease course (%)
tongue, unresponsive upper
ar nerve injury, conductive
92
, pulmonary hemorrhage 85
zing 80
r arthritis, arthralgias 67
sis, dacrocystis 52
is, subcutaneous nodules, 46
ranial neuropathy, meningitis 20
lesions (brain, renal, lung,
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difficult. Common biopsy sites include the upper respira-
tory tract or the lungs although even these sites do not
have consistent biopsy success rates. As a result, a charac-
teristic biopsy demonstrating GPA features is confirmatory,
but not necessary.
The changing landscape of GPA treatment
Although nonspecific intensive immunosuppressants
have long been the successful mainstay of treatment for
GPA, effective alternatives are on the horizon for pa-
tients with toxicity or unique immunosuppressant con-
cerns. Current first-line treatment for inducing GPA
remission consists of cyclophosphamide and glucocorti-
coids. This immunosuppressant regimen has saved thou-
sands of lives, dropping the mortality rate from nearly
100 percent to 4 to 13 percent [1].
A randomized controlled trial with 149 ANCA-
associated vasculitis patients demonstrated that cyclo-
phosphamide can be effectively delivered in one of two
forms: monthly IV treatments (15mg/kg) or daily oral
treatments (2mg/kg/day). This cyclophosphamide dose
was maintained until remission was achieved, up to a
maximum of nine months [9]. While there is debate re-
garding the optimal glucocorticoid therapy regimen, pa-
tients with severe kidney or lung manifestations are
typically treated with initial methylprednisone IV pulses
for three days followed by oral prednisone, 1mg/kg/day.
Those with less severe GPA forms may be treated with
daily oral prednisone alone. Use of corticosteroids for
greater than six months is not advised as it significantly
increases patients’ infection risk [7].
While this therapy regimen has marked success, the
significant morbidity associated with these medications
cannot be ignored. Of particular concern is cyclophos-
phamide’s association with an increased risk of infertility,
transitional cell carcinoma of the bladder, and myelopro-
liferative disorders [4]. Infection, the primary cause of
death in the year following an initial GPA event, is also a
significant risk.
With these side effects in mind, various alternative treat-
ments are being actively researched and tested. The most
promising alternative treatment to cyclophosphamide is ri-
tuximab, a chimeric B-cell monoclonal antibody. Rituxi-
mab has been explored as an effective choice for both
inducing remission in ANCA-associated vasculitides. In
July 2010, the New England Journal of Medicine reported
Stone et al.’s multicenter, randomized, double-blind,
double-dummy, noninferiority trial of rituximab against
cyclophosphamide. This landmark trial successfully dem-
onstrated noninferiority of rituximab to cyclophosphamide
in inducing remission of ANCA-associated small-vessel
vasculitis [10]. As such, rituximab (375mg/m2 for four
weeks) is increasingly being used as substitute for GPAtreatment. In the current case, the ability to provide rituxi-
mab as a fertility-protecting alternative made a significant
impact in the patient’s comfort with the treatment and
subsequent quality of life.
Conclusions
Recognizing GPA is a true diagnostic challenge. Detailed
history and physical examination are crucial to compre-
hensive understanding of presenting symptoms. Maintain-
ing a degree of suspicion for vasculitides when a patient
presents with constitutional symptoms or inflammation
with antibiotic failure will allow for early recognition of
this potentially devastating condition. Despite significant
advances in GPA treatment, 50 percent of GPA patients
experience some form of long-term disability due to the
common rapid progression of the disease. In the current
case, our patient may face long-term challenges associated
with the loss of more than half of her teeth as well as left-
sided hearing loss. Despite these unfortunate sequelae, ef-
fective recognition and treatment of this deadly condition
prevented dialysis dependence, intensive care unit admis-
sion and possible death. Future advances in GPA diagnosis
as well as increased awareness of the multiple possibilities
of presentation will allow physicians to continue protect-
ing the health of their patients through early GPA diagno-
sis and appropriate, prompt management.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
image. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
Key points
GPA is a deceptive mimic of infection or malignancy,
manifesting in numerous forms most often within the air-
way or the kidney.
In all branches of medicine, maintaining an index of
suspicion for GPA allows physicians to make early diag-
noses, which significantly reduces the morbidity/mortal-
ity of the condition.
Rituximab is an effective substitute for cyclophospha-
mide in acute GPA treatment regimens.
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